background
background
AKBA
Akebia Therapeutics
$3.90
+0.02
+0.52%
Earnings Expectation?
Beat
Meet
Miss
Expected Price Action?
Up
Flat
Down

Akebia Therapeutics Beat Consensus Estimates

Thursday, May 8, 2025 at 7:00 AM ET

Akebia Therapeutics (AKBA) reported earnings of $0.03 per share on revenue of $57.34 million for the first quarter ended March 2025. The consensus estimate was a loss of $0.03 per share on revenue of $45.21 million. The company beat consensus estimates by 200.00% while revenue grew 75.84% on a year-over-year basis.

Akebia Therapeutics Inc is a biopharmaceutical company. It is engaged in the development of proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease.

Earnings Whisper Grade
Earnings Whisper GradeEarningsWhisper®edarG-
Power Rating
-
Reported Earnings
$0.03
Earnings Whisper®
-
Consensus Estimate
$-0.03
Earnings Surprise
200.0%
Earnings Growth
133.3%
Reported Revenue
$57.34 Mil
Revenue Estimate
$45.21 Mil
Revenue Surprise
26.8%
Revenue Growth
75.8%